Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bempegaldesleukin + nivolumab + axitinib
- Development stage
- Phase 1
- Lead developer
- Nektar Therapeutics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**Bempegaldesleukin + nivolumab + axitinib** is an investigational combination regimen for advanced or metastatic renal cell carcinoma (RCC). - **Bempegaldesleukin** is a PEGylated recombinant interleukin-2 (IL-2) cytokine prodrug engineered to preferentially stimulate the IL-2 pathway via the CD122 (IL-2 receptor βγ) complex, thereby activating and expanding CD8^+ T cells and natural killer (NK) cells, with minimal expansion of immunosuppressive regulatory T cells. - **Nivolumab** is a monoclonal antibody checkpoint inhibitor targeting the programmed cell death 1 (PD-1) receptor, blocking PD-1/PD-L1 interaction and boosting T cell–mediated immune responses. - **Axitinib** is a small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), acting as an antiangiogenic targeted therapy. This triple combination is studied for its synergistic potential to enhance antitumor immunity and inhibit tumor angiogenesis, primarily in renal cell carcinoma.
- Other names
- bempegaldesleukin + nivolumab + axitinib
02
Targets
IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)VEGFR (VEGFR family)
Beyond the preview
Go deeper on bempegaldesleukin + nivolumab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bempegaldesleukin + nivolumab + axitinib.